Document:

EX-10.1

 Exhibit 10.1 

EMPLOYMENT AGREEMENT AMENDMENT 

OXiGENE, Inc. (the “Company”) and Barbara D. Riching (“Employee”) hereby agree to amend the February 27, 2013 employment agreement
between Company and Employee, for good and valuable consideration, the receipt and sufficiency of which are hereby mutually acknowledged, to add the following provisions: 

1. If the Company terminates Employee’s employment without Cause or Employee resigns her employment with Good Reason, the Company will provide Employee
the following termination compensation and benefits, in addition to and separate and apart from those required under applicable federal and state law, subject to Employee’s execution of an employment release in a form prepared by and suitable
to the Company: 
 (a) payments equal to Employee’s then-current base salary for a period of six (6) months, payable in accordance
with the Company’s normal payroll cycle and subject to applicable withholdings and deductions, including those required and authorized by law; and 

(b) should Employee timely elect and be eligible for COBRA coverage, payment of Employee’s COBRA premiums for Employee and
Employee’s immediate family’s medical and dental insurance coverage for a period of six (6) months; provided, that the Company will have no obligation to provide such coverage if Employee becomes eligible for medical and dental
coverage with another employer, provided that if the payment of the Employee’s premiums would violate the nondiscrimination rules or cause the reimbursement of claims to be taxable under the Patient Protection and Affordable Care Act of 2010 or
Section 105(h) of the Internal Revenue Code of 1986, as amended (the “Code”), the Company paid premiums shall be treated as taxable payments and be subject to imputed income tax treatment to the extent necessary to eliminate any
discriminatory treatment or taxation under the Patient Protection and Affordable Care Act or Section 105(h) of the Code. Employee will give prompt written notice to the Company on attaining such eligibility. 

2. If the Company terminates Employee’s employment without Cause or Employee resigns her employment with Good Reason in the one year period following the
effective date of a Change in Control, the Company will provide Employee the following termination compensation and benefits, in addition to those required under applicable federal and state law: 

(a) a lump sum payment of an amount equal to six (6) months of Employee’s then-current base salary, subject to applicable
withholdings and deductions, including those required and authorized by law; and 
 (b) all stock options, stock appreciation rights,
restricted stock, and other incentive compensation granted to Employee by the Company will vest and be immediately exercisable and Employee may exercise all such vested options and rights, and will receive payments and distributions accordingly,
subject to the terms of the applicable Company stock plan documents that govern stock options, stock appreciation rights, restricted stock, and other applicable incentive compensation; and 

 (c) should Employee timely elect and be eligible for COBRA coverage, payment of Employee’s
COBRA premiums for Employee and Employee’s immediate family’s medical and dental insurance coverage for a period of six (6) months; provided, that the Company will have no obligation to provide such coverage if Employee becomes
eligible for medical and dental coverage with another employer, provided that if the payment of the Employee’s premiums would violate the nondiscrimination rules or cause the reimbursement of claims to be taxable under the Patient Protection
and Affordable Care Act of 2010 or Section 105(h) of the Code, the Company paid premiums shall be treated as taxable payments and be subject to imputed income tax treatment to the extent necessary to eliminate any discriminatory treatment or
taxation under the Patient Protection and Affordable Care Act or Section 105(h) of the Code. Employee will give prompt written notice to the Company on attaining such eligibility. 

3. Definitions: 
 (a) “Cause” means:
(a) Employee’s substantial failure to perform any of her duties as Chief Financial Officer or to follow reasonable, lawful directions of the Board or any officer to whom Employee reports; (b) Employee’s willful misconduct or
willful malfeasance in connection with her employment; (c) Employee’s commission of, conviction of, or plea of nolo contendere to, any crime constituting a felony under the laws of the United States or any state thereof, or any other crime
involving moral turpitude; (d) Employee’s material breach of any provision of this Agreement, the Company’s bylaws or any other written agreement with the Company; (e) Employee’s engaging in misconduct that causes
significant injury to the Company, financial or otherwise, or to its reputation; or (f) any act, omission or circumstance constituting cause under the law governing this amendment. 

(b) “Good Reason” means the Company: (a) materially reduces Employee’s title or responsibilities; (b) relocates its
US headquarters more than sixty (60) miles from its current location (unless the relocation results in the headquarters being closer to Employee’s residence); (c) materially reduces Employee’s base salary; or (d) breaches a
material term of this Agreement and within ninety (90) days of the initial occurrence of one of the foregoing events, Employee notifies the Company in writing that the event has occurred and the nature of the event, Employee provides the
Company at least thirty (30) days following the date the Company receives Employee’s notice to cure the event and, if the Company fails to cure, Employee actually terminates Employee’s employment within sixty (60) days following
the date the Company receives Employee’s notice. Good Reason must also meet the requirements for a good reason termination in accordance with Treasury Regulation §1.409A-1(n)(2), and any successor statute, regulation and guidance thereto.

 (c) Change in Control means: (i) any “Person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange
Act of 1934, as amended) becomes the “Beneficial Owner” (as defined in Rule 13d-3 under said Act), directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the total voting power represented
by the Company’s then outstanding voting securities (excluding for this purpose any such voting securities held by the Company or its affiliates or by any employee benefit plan of the Company) pursuant to a transaction or a series of related
transactions which the Board of Directors does not approve; (ii) a merger or consolidation of the Company whether or not approved by the Board of 

 
Directors, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining
outstanding or by being converted into voting securities of the surviving entity or the parent of such corporation) at least 50% of the total voting power represented by the voting securities of the Company or such surviving entity or parent of such
corporation, as the case may be, outstanding immediately after such merger or consolidation; (iii) the stockholders of the Company approve an agreement for the sale or disposition by the Company of all or substantially all of its assets; or
(iv) a change in the composition of the Board of Directors, as a result of which fewer than a majority of the directors are Incumbent Directors, and provided in each such case the Change in Control also meets the requirements of a “Change
in Control Event” within the meaning of Section 409A(a)(2)(A)(v) of the Code and Treasury Regulation Section 1.409A-3(i)(5). “Incumbent Directors” mean the directors who either (A) are directors of the Company as of the
date of this Agreement, or (B) are elected, or nominated for election, to the Board of Directors with the affirmative votes of at least a majority of the Incumbent Directors at the time of such election or nomination (but shall not include an
individual whose election or nomination is in connection with an actual or threatened proxy contest relating to the election of directors to the Company). 

5. This amendment is an involuntary separation pay plan (as defined in Treasury Regulation 1.409A-1(b)(9)(iii)) and will be construed consistently with that
provision. All references to a “termination” of employment in this Amendment shall be deemed to require Employee to incur a “separation from service” as that term is defined in Treasury Regulation 1.409A-1(h) before payment of
any separation benefits commences. 
 6. Nothing in this amendment alters any other terms and conditions in the February 27, 2013 employment agreement
between the Company and Employee, which remains in full force and effect. Nothing in this amendment alters any other terms and conditions applicable to Employee’s employment with the Company, including the at-will nature of the employment
relationship between the Company and Employee. The Company and Employee can still terminate the employment relationship at any time, for any reason or no reason, and with or without notice. This amendment sets forth the entire agreement between the
Company and Employee regarding its subject matter. The Company and Employee did not make any promises or representations to each other regarding the subject matter of this amendment that do not appear in this amendment. No variations or
modifications to this amendment are valid unless agreed to in writing by the Company and Employee. If any provision in this amendment is found to be unenforceable, it will not affect the enforceability of the remaining provisions. The Court may
enforce all remaining provisions to the extent permitted by law. The failure of the Company to seek enforcement of any provision of this amendment in any instance or for any period of time will not be construed as a waiver of that provision or of
the Company’s right to seek enforcement of such provision in the future. 
 7. The validity, interpretation, enforceability, and performance of this
amendment must be governed by and construed in accordance with the laws of the State of California, exclusive of its choice-of-law rules. Any action arising under or relating to this amendment must be commenced and maintained in the federal or state
courts as applicable in San Francisco County, California. The parties consent to the jurisdiction of the San Francisco County, California federal and state courts, as applicable, for any claims or lawsuits filed there arising from or relating to
this amendment. 

							
		 		 	OXiGENE, Inc.
			
	Dated: November 12, 2014	 		 	 /s/ David J. Chaplin

		 		 	By:	 	David Chaplin, M.D., Ph.D.
			
		 		 	Chief Executive Officer
			
	Dated: November 12, 2014	 		 	 /s/ Barbara D. Riching

		 		 	Barbara D. RichingEX-10.2

 Exhibit 10.2 

CONSULTING AGREEMENT 

This CONSULTING AGREEMENT, made effective July 21, 2014 (the “Effective Date”), by and between OXiGENE, Inc., a Delaware
corporation (“OXiGENE”), having a principal place of business at 701 Gateway Boulevard, Suite 210, South San Francisco, California 94080 and Tekgenics, Inc. (“Consultant”), having an address of 3901 Point Rd. Mobile AL 36619
(OXiGENE and Consultant may be referred to individually as a “Party” or collectively as the “Parties.”) 

WHEREAS, OXiGENE is engaged in the design and development of vascular targeting drugs aimed at the shut down of blood flow to
cancerous tumors and various ocular diseases; 
 WHEREAS, OXiGENE desires to retain Consultant to provide certain consulting
services for OXiGENE as indicated herein; and 
 WHEREAS, Consultant desires to provide such services to OXiGENE, in
accordance with the terms and conditions herein contained. 
 NOW, THEREFORE, in consideration of the foregoing and of the mutual covenants and agreements
set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows: 

1. Services. Based upon Consultant’s skills and experience, and subject to the terms and conditions herein, Consultant will provide to OXiGENE
consulting services as requested by OXiGENE and as described in Exhibit A, which is attached hereto and incorporated herein by reference (the “Services”). Consultant agrees to use best efforts in its performance of the Services during the
Term and shall diligently perform the Services in accordance with accepted industry practices, applicable laws and regulations, and the highest professional standards. 

2. Consideration. OXiGENE agrees to pay Consultant up to a budget cap specified in Exhibit A for Services actually performed in accordance with this
Agreement and Exhibit A at OXiGENE’s request and invoiced. Total charges for all professional service fees, including reasonable travel and necessary out of pocket expenses incurred by Consultant with the advance approval of OXiGENE will not
exceed the budget cap specified in Exhibit A. In no event will Consultant perform work requiring expenditures in excess of the budget without prior written approval from OXiGENE. Notwithstanding anything in this Agreement or the Exhibits to the
contrary, the aggregate annual compensation payable to Consultant under this Agreement and all Exhibits hereto, exclusive of travel, living and out of pocket expenses actually incurred by Consultant, cannot and will not exceed the sum of one hundred
twenty thousand dollars ($120,000) per calendar year. 
 3. Confidentiality. In connection with the Agreement, the following provisions with respect
to confidentiality and non-disclosure will apply: 
 3.1 From time to time hereafter, OXiGENE may make available or otherwise disclose to
Consultant information which is non-public, confidential and proprietary to OXiGENE and which by nature is material to the trading or market value of OXiGENE’s stock and other securities, including, without limitation, information related to
OXiGENE’s business and drugs and compounds developed or under development by OXiGENE (collectively, “Confidential Information”). Confidential Information includes not only written information, or copies, abstracts or summaries thereof
or references thereto in any other document, but also information transferred verbally or by other means. 
 3.2 Consultant will keep secret
and confidential, will not disclose, discuss, reproduce, distribute, or otherwise release any Confidential Information to any third party without the prior written consent of OXiGENE and will not purchase, sell, or enter into any other transaction
involving any OXiGENE securities 

 
in violation of applicable federal and state securities laws. Consultant agrees to take reasonable precautions to protect the confidential and proprietary nature of all Confidential Information
and to prevent its disclosure to third parties. Consultant agrees not to make any public announcements with respect to OXiGENE or its business. Consultant further agrees to use the Confidential Information only in connection with Consultant’s
performance of the Services. 
 3.3 Consultant agrees and acknowledges that (i) all Confidential Information remains the exclusive
property of OXiGENE; and (ii) OXiGENE reserves all rights with respect to all information relating to OXiGENE’s products, including, but not limited to, the right to apply for patents. Consultant shall assure that upon termination of this
Agreement or completion of the Services set forth in Exhibit A, all Confidential Information furnished to Consultant shall be returned to OXIGENE promptly at its request, except that Consultant may retain one copy for the sole purpose of ensuring
compliance with this Agreement. Notwithstanding the forgoing, Consultant shall not be required to remove or destroy any Confidential Information that are contained on backup media as a result of systematic backups of Consultant’s computer
system, provided that Consultant shall not access such backup media for the purpose of recovering the Confidential Information. 
 3.4
OXiGENE is disclosing the Confidential Information to Consultant under the confidentiality agreement exclusion in Rule 100(b)(2)(ii) of Regulation FD (Fair Disclosure), adopted by the Securities and Exchange Commission. Trading OXiGENE
securities while in possession of Confidential Information or providing others with Confidential Information that they then use to trade OXiGENE securities may subject Consultant and others who receive Confidential Information to liability for
insider trading. 
 3.5 Consultant agrees that the provision of this Section 3 are fair and reasonable, that money damages would not be
sufficient remedy for any breach by the Consultant of this Section 3 and that, in addition to all other remedies, OXiGENE shall be entitled to specific performance and injunctive or other equitable relief for such breach. 

4. Term. 
 4.1 This Agreement shall
commence on the Effective Date and shall continue until December 31, 2015, or such later time as the Services described in Exhibit A have been completed, unless either Party terminates this Agreement earlier in accordance with Section 4.2.

 4.2 Either Party may terminate this Agreement at any time upon (7) days’ prior written notice, provided, however, that either
Party may terminate this Agreement immediately in the event the other Party’s material breach. 
 5. Independent Contractor. 

5.1 The Parties acknowledge and agree that Consultant (i) offers professional services to the general public; (ii) currently
provides and/or is otherwise free to provide professional services to other clients (to the extent not in conflict with the terms of this Agreement); and (iii) is subject to the control and direction of OXiGENE only as to the end result of the
Services, and is otherwise free to perform the Services in a time, place and manner consistent with Consultant’s professional judgment. Accordingly, the Parties acknowledge and agree that Consultant’s affiliation with OXiGENE is that of an
independent contractor and as such, Consultant will not be considered for any purpose to be an agent, partner or joint venturer of OXiGENE. Neither OXiGENE nor Consultant will have any obligation, responsibility or authority to act on behalf of or
in the name of the other, or to bind the other in any manner whatsoever. As an independent contractor, Consultant shall be solely responsible for all applicable taxes arising from payments received from OXiGENE, including, but not limited to, social
security, self-employment taxes and disability insurance. 

  
 2 

 6. Ownership of Intellectual Property. 

6.1 OXiGENE owns all work prepared or created under this Agreement, including all intellectual property rights in such work (the “OXiGENE
Work”). Consultant agrees to maintain and furnish to OXiGENE complete and current records of all inventions or discoveries made under this Agreement, including without limitation the OXiGENE Work and disclose to OXiGENE in writing any such
inventions. Consultant agrees to assign to OXiGENE ownership of the OXiGENE Work, including intellectual property rights therein. OXiGENE will bear the expense of such proceedings; provided that, any patent or other legal right so issued to
Consultant shall be assigned by Consultant to OXiGENE without charge by Consultant. Consultant shall provide to OXiGENE, in writing, a full, signed statement of all inventions in which it participated during the course of the consulting arrangement.
Consultant further agrees to use best efforts in the course of performing the Services to prevent any violation or infringement of any right, patent, copyright, trademark or right of privacy, or any act that would constitute libel or slander against
or violate any other rights of any person, firm or corporation. 
 6.2 At any time during or after the Term, Consultant agrees that it will
fully cooperate with OXiGENE, its attorneys and agents, in the preparation and filing of all papers and other documents as may be required to perfect OXiGENE’s rights in and to any OXiGENE Work, including, but not limited to, joining in any
proceeding to obtain letters patent, copyrights, trademarks or other legal rights of the United States and of any and all other countries on such inventions, provided that OXiGENE will bear the expense of such proceedings. Consultant hereby
designates OXiGENE as its agent, and grants to OXiGENE a power of attorney with full power of substitution (which power of attorney shall be deemed coupled with an interest), for the purpose of effecting the foregoing assignments from Consultant to
OXiGENE. 
 7. No Conflicts. Consultant represents that Consultant has not entered into any other contract or other arrangement that would impair
OXiGENE’s rights or Consultant ability to perform its obligations under this Agreement, and the performance of Consultant duties as a consultant to OXiGENE pursuant to the terms of this Agreement will not breach any agreement by which
Consultant is bound, including any agreement limiting the use or disclosure of proprietary information acquired in confidence prior to an engagement by OXiGENE. OXiGENE acknowledges that Consultant provides similar services to other organizations
that may be competitive with OXiGENE. During the Term, Consultant will not, without first advising OXIGENE in writing, enter into any other agreement, arrangement, understanding or other relationship pursuant to which it would be obligated to render
advice and services to a commercial entity in OXiGENE’s “Field of Interest”. The term “Field of Interest” with respect to OXIGENE currently means the field of vascular disrupting agents. OXIGENE may modify the definition of
Field of Interest by written notice to Consultant based on activities in which OXIGENE is then engaged or in which OXIGENE then proposes to be engaged. 

8. Certification of Non-Debarment. Consultant the event that during the Term of this Agreement, Consultant becomes debarred or receives notice of an
action or threat of an action with respect to its debarment, Consultant shall notify OXiGENE immediately. Consultant hereby certifies that it has not and will not use in any capacity the services of any individual, corporation, partnership or
association that has been debarred. In the event that Consultant becomes aware of the actual or threatened debarment of any person or entity providing services hereunder, which directly or indirectly relate to services provided under this Agreement,
Consultant shall notify OXiGENE immediately. 
 9. Notice. All notices and other communication hereunder shall be in writing and delivered by hand,
nationally recognized express courier, or by first class registered or certified mail, return receipt requested, postage pre-paid, addressed as follows: 
  

			
	If to OXiGENE:	  	If to the Consultant:
		
	OXiGENE, Inc.	  	Tekgenics, Inc.
	701 Gateway Boulevard	  	3901 Point Rd.
	South San Francisco, CA 94080	  	Mobile AL 36619
	Attn: Chief Executive Officer	  	Attn: William D. Schwieterman, M.D.

  
 3 

 10. Non-Assignability. This Agreement is personal in nature and may not be assigned by Consultant. This
Agreement shall be binding upon, and inure to the benefit of, OXiGENE and its successors and assigns. 
 11. Miscellaneous. 

11.1 Survival. The following provisions shall survive the termination or expiration of this Agreement: Articles 2, 3, 5, 6, 9, 10 and 11. 

11.2 Entire Agreement. This Agreement constitutes the entire agreement between the Parties with respect to the subject matter hereof,
and supersedes and replaces any prior agreement or understanding, whether written or oral. This Agreement may not be amended, modified or supplemented, except by an instrument in writing executed by OXiGENE and Consultant. 

11.3. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of California, without
regard to the principles thereof respecting conflicts of law. 
 11.4. Section Headings. The section headings on this Agreement are
for reference purposes only and shall not affect in any way the meaning of interpretation of this Agreement. 
 11.5. Counterparts.
The Agreement may be executed in two or more counterparts, all of which shall be considered one and the same agreement. The Agreement shall become a binding agreement when one or more counterparts shall have been signed by each of the Parties whose
signature is provided for below. 
 11.6. Severability. If any of the provisions of this Agreement shall be held by a court of
competent jurisdiction to be void or unenforceable, the balance of the provisions of this Agreement shall remain in effect and be enforced so as to give effect as nearly as possible to the intentions of the Parties hereto. 

[Signature Page to Follow] 

  
 4 

 IN WITNESS WHEREOF, each of the Parties hereto has executed this Agreement as of the date first written above.

  

			
	OXiGENE, Inc.
		
	By:	 	 /s/ David J. Chaplin, Ph.D.

		 	  

	Name:	 	David J. Chaplin, Ph.D.
	Title:	 	Chief Executive Officer
	
	CONSULTANT
		
	By:	 	/s/ William D. Schwieterman, M.D.
		 	  

	Name:	 	William D. Schwieterman, M.D.
	Title:	 	President

  
 5 

 Exhibit A 

1. Services. Consultant agrees to provide the following consulting services upon OXiGENE’s request: 

 

	 	•	 	regulatory development advice; and 

  

	 	•	 	Such other services as OXiGENE may request in writing (including email) from time to time. 

 2.
Compensation. 
 2.1 As full compensation for Services provided on a time and materials basis, OXiGENE will pay to Consultant four
hundred dollars ($400) per hour. Consultant shall document and record all time spent in the performance of the Services to the reasonable satisfaction of OXiGENE. 

2.2 The amount of remuneration authorized under this Exhibit A shall be up to but not more than the amount set forth in OXiGENE purchase order
number 1657, as may be amended from time to time by OXiGENE in its sole discretion; provided, however, that the aggregate annual compensation payable to Consultant under this Agreement and all Exhibits hereto, exclusive of travel, living and out of
pocket expenses actually incurred by Consultant, cannot and will not exceed the sum of one hundred twenty thousand dollars ($120,000) per calendar year. 

2.3 The Parties agree that Services performed and travel and out-of-pocket expenses incurred by Consultant beyond the amount authorized herein
shall not be subject to compensation without the prior written consent of OXiGENE. 
 3. Term. 

3.1 This Exhibit A shall commence on the Effective Date of the Agreement and shall continue through the later of December 31, 2015, or
such later time as the Services described in Exhibit A have been completed, unless either Party terminates this Amendment earlier in accordance with Section 3.2. 

3.2 Either Party may terminate this Exhibit A at any time upon seven (7) days’ advance notice, provided, however, that either Party
may terminate this Agreement immediately in the event of the other Party’s material breach. 
 4. Invoices. Consultant will provide to OXiGENE
invoices for Services rendered as requested hereunder. Payment of invoices submitted with the required detail, delineated herein, will be made within thirty (30) days of OXiGENE’s receipt of such invoice. Should any part of the invoice be
in dispute, OXiGENE shall pay the remainder of the undisputed amount according to the terms and conditions described herein while said dispute is being resolved. 

All invoices must be issued to: “OXiGENE, Inc., Attn: Accounts Payable, 701 Gateway Blvd., South San Francisco, CA 94080” and forwarded via e-mail
to ap@oxigene.com for payment. 
 To avoid any delay in payment, all invoices should clearly contain the detail required by OXiGENE, including: 

Consultant’s name & full mailing address 
 Whom to
make the check payable to and their Tax ID # if applicable 
 Invoice date 

Total amount due & payment currency 
 Description of
services rendered/project and/or study number and/or period ending 
 Invoices that do not contain the required detail will be rejected and must be
resubmitted in order to be processed and paid. 

  
 6 

 IN WITNESS WHEREOF, the Parties hereto have caused this Exhibit A to be executed and made effective by their duly
authorized representatives. 
  

									
	OXiGENE, INC.	 		 	CONSULTANT
					
	By	 	 /s/ David J. Chaplin, Ph.D.
	 		 	By	 	 /s/ William D. Schwieterman, M.D.

		 	  
	 		 		 	  

					
	Name:	 	David J. Chaplin, Ph.D.	 		 	Name:	 	William D. Schwieterman, M.D.
					
	Title:	 	Chief Executive Officer	 		 	Title:	 	President
					
	Date	 	 14th August 2014
	 		 	Date:	 	 August 14th, 2014

				
		 		 		 	EIN: 35-2172996

  
 7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}]]